SciSparc Ltd. (SPRC) Form 6-K — Jul 15, 2026
SciSparc announced the initiation of a Phase IIb clinical trial for its proprietary drug candidate SCI-110 at Hannover Medical School in Germany for the treatment of Tourette Syndrome in adults. The trial is designed as a randomized, double-blind, placebo-controlled, cross-over study evaluating the efficacy and safety of SCI-110, with the primary endpoint measuring changes in tic severity at weeks 12 and 26.
Key figures
- Endpoint weeks
- [12,26]
- Patient age range
- 18-65
- Phase iia tic reduction percent
- 21
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.